naion and glp 1 Glucagon-like peptide-1 receptor agonists the risk of nonarteritic anterior ischemic optic neuropathy: Evidence from a global real-world cohort GLP-1s are changing bodies… but

The cell evidence establishes biological plausibility, not clinical proof

This newly published case report describes pregnancy in lysinuric protein intolerance (LPI) complicated by established immune dysregulation, severe thrombocytopenia and episodes of hyperammonaemia, a combination not previously reported

Endocrinology 152 , 31033112 (2011)

Higher-dose oral semaglutide and other developments Novo Nordisk has developed higher-dose versions of oral semaglutide (25 mg and 50 mg) to target obesity and provide stronger blood sugar and weight loss effects

Katrin Svensson, PhD, an associate professor of pathology at Stanford University who directs a lab doing preclinical peptide research, goes further